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The present study is focused on exploring the Acetylcholinesterase and Butyrylcholinesterase inhibitory activity of Huperzine-A 
in silico and in vitro. In this study, Huperzine-A-A was docked with Acetylcholinesterase and Butyrylcholinesterase. Docking 
studies revealed the excellent interaction of Huperzine-A-A with these targets. The result of present study provides insight for the  
in vitro studies. The in vitro studies the enzyme kinetics of Huperzine-A-A via Lineweaver brooks plot revealed the kinetics and 
non-competitive inhibitory nature of the later. Further studies on Huperzine-A-A are necessary to develop and establish its role on 
brain cholinergic system and cognitive deficits which may serve a stepping stone in CNS medication.  
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Acetylcholinesterase and Butyrylcholinesterase have 
been studied for decades. Early work showed that 
cholinesterase has a critical role in nerve impulse 
transmission
1
. They are the chemical mediator and 
have an important role in entorhinal cortex and 
hippocampus function. It has been also claimed that 
Butyrylcholinesterase (BuChE) has the ability to 
substitute acetylcholinesterase (AChE) in the 
hydrolysis of ACh
2
. The Involvement of AChE and 
BuChE is reported in cognitive functions and brain 
cholinergic
3
. Acetylcholine and Butyrylcholine is 
known as the learning neurotransmitter and is involved 
in muscle contraction as well. Cholinesterase inhibitors 
increase the amount of ACh and Buch at the neuronal 
synaptic cleft by inhibiting the enzyme responsible for 
the hydrolysis of ACh and Buch consequently improve 
neuronal transmission. Its potency of cholinesterase 
inhibition whether acetyl or butyl is similar or superior 
to that of physostigmine, galanthamine, donepezil and 
tacrine
4
. Huperzine regarded as a Nootropic agent is a 
plant-based alkaloid. It is a compound extracted from 
the herbs of the Huperziceae family. Huperzine-A has 
been used for centuries to treat fever, inflammation, 
blood disorders, and schizophrenia
5
. Huperzine-A acts as 
a potent, highly specific and reversible inhibitor of 
acetylcholinesterase that crosses the blood–brain barrier, 
which means that it stops an enzyme from breaking down 
acetylcholine which results in increases in acetylcholine. 
Huperzine-A-A appears to be a relatively safe compound 
from animal studies of toxicity and studies in humans 
showing no side-effects at dosages routinely 
supplemented with. Huperzine-A is in preliminary trials 
for usage in fighting Alzheimer's disease as well
6,7
.  
The Present study aims to study the Acetylcholinesterase 
and Butyrylcholinesterase inhibitory activity of 
Huperzine-A-A via in silico and in vitro studies. 
 
Materials and Methods 
Chemicals 
Acetylcholinesterase, Butyrylcholinesterase, Galant 
amine, DTNB, and Huperzine-A were procured from 
Sigma Aldrich Company (India) and other analytical 
grade laboratory reagents for procured from SRL  
Chemicals (India). 
 
In vitro enzyme inhibition studies  
The activity of cholinergic markers AChE and 
BuChE were estimated spectrophometrically using the 
Elisa reader according to the method of Ellman
8
. The 
assay is a spectrophotometric method that involves 
two linked reactions to produce a coloured compound. 
Briefly, 10 mM DTNB in 0.1 M Tris–HCl buffer (pH 8.0), 
100 μL of the supernatant, and 30 mM 
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acetylthiocholine iodide as substrate were added for 
AChE estimation. For BuChE estimation, 10 mM DTNB 
in 0.1 M Tris–HCl buffer (pH 8.0), 300 μL of supernatant, 
and 7.5 mM butyrylthiocholine iodide as substrate were 
added. Absorbance was measured at 412 nm for 3 min at 
30 sec intervals using a spectrophotometer. AChE activity 
is expressed as micromoles of acetylthiocholine iodide 
(ATCh) hydrolyzed per milligram of protein per min, and 
BuChE activity is expressed as micromoles of 
butyrylthiocholine iodide hydrolyzed per milligram of 
protein per min. One unit is defined as 1 mole of 
acetylthiocholine hydrolyzed per min per milligram  
of protein
9
. 
 
Enzyme inhibition kinetics  
The kinetic parameters were calculated by using 
Lineweaver- Burk plots 1/V0 = (Km/Vmax)·(1/[S]) + 
1/Vmax, where V0 and Vmax are the initial and maximal 
reaction velocities, [S] is the concentration of 
substrate, and Km is the Michaelis-Menten constant
10
. 
The Km for the immobilized AChE and BuChE was 
determined by injecting 1 L substrate ATCh in 
aqueous solution at the concentration range of  
0.005-5 mM. In order to determine the inhibitory 
potency (IC50), 0.1 mM of ATCh with increasing 
concentration of inhibitor (0.2-500 M) was injected 
into both the AChE and BuChE, respectively. All 
samples were analyzed five times. Origin Pro  
8.5 software was used to calculate Km according to 
Lineweaver-Burk plots and fit the inhibition curve
11
. 
 
In silico docking studies 
Software 
Python 2.7 language was downloaded from 
www.python.com
12
, Molecular graphics laboratory 
(MGL) tools and Autodock 4.2
13
 was downloaded from 
www.scripps.edu, Discovery Studio visualizer 4.1
14
 was 
downloaded from www.accelerys.com. Calculations 
were performed on Windows 8.0 Operating System. 
 
Protein preparation 
The three-dimensional crystalline structures of 4 
targeted proteins (Table 1) were retrieved from the 
Protein Data Bank (http://www.rcsb.org/). The retrieved 
protein was PBD ID: 4EY7 for Acetylcholinesterase and 
PBD ID: 1ITB for Butyrylcholinesterase. The coordinates 
of the structures were complexed with water molecules, 
and other atoms which are responsible for increased 
resolution and therefore the water molecules and  
het-atoms were removed using discovery studios and 
saved in. pdb format. 
 
Docking analysis 
Docking studies were performed to analyze 
interactions of Huperzine with Acetylcholinesterase and 
Butyrylcholinesterase targets
15
. The three-dimensional 
crystalline structures of 4 proteins were obtained from 
the Protein Data Bank (http://www.rcsb.org/). These 
protein were PBD ID: 4EY7 for Acetylcholinesterase 
and PBD ID: 1ITB for Butyrylcholinesterase. The 
structurally refined protein .pdb files were converted 
to .pdbqt files using grid module of autodock tools 
1.5.6. Charges were assigned to the ions to the 
proteins manually wherever necessary. The 2D and 
3D chemical structures of Huperzine (Molecular 
formula: C15H18N2O; Molecular weight 242.32 g/M) 
was retrieved (http://puBuChEm.ncbi.nlm.nih.gov/). 
These .sdf and .mol files obtained from PuBuChEm 
were converted into .pdb files using Marwin Sketch 
(http://www.chemaxon.com/marvin/ ketch/index.jsp). 
These .pdb files were converted to .pdbqt using ligand 
preparation module of autodock tools 1.5.6. The 
docking analysis of Huperzine was carried out using 
the Autodock tools (ADT) v 1.5.4 and autodock v 4.2 
programs. Huperzine was docked to all the target 
protein complexes with the molecule considered as a 
rigid body. The search was carried out with the 
Lamarckian Genetic Algorithm; populations of 100 
individuals with a mutation rate of 0.02 have been 
evolved for ten generations. The remaining 
parameters were set as default. The Docked structure 
was then visualized using Discovery Studio 2016 for 
obtaining the binding interactions
16
. 
 
Statistical analysis 
The results are expressed as mean ± standard error 
of the mean. Experiments were always performed in 
triplicates. Statistical comparison was performed 
using analysis of variance (ANOVA) followed by 
Bonferroni's test (*P< 0.001) 
 
Results 
The attachment of Covalent bond to the enzyme 
surface may affect its ultimate activity
17
. In order to 
verify the catalytic activity of the AChE and BuChE 
kinetic i.e. Km, Vmax and IC50 were determined. The 
Km and Vmax values of AChE and BuChE were 
determined by varying the substrate ATCh 
Table 1 — Molecular docking studies of Huperzine-A with 
acetylcholinesterase and Butyrylcholinesterase 
Target Resolution PDB ID Binding 
energy 
Inhibitory 
constant (µM) 
Acetylcholinesterase 2.35Å 4EY7 −5.01 181.21 
Butyrylcholinesterase 2.50Å 1ITB −8.02 1.33 
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concentration under the described experimental 
conditions. The Lineweaver-Burk plots of the double 
reciprocal plots of 1/[velocity] and 1/[substrate] and 
Vmax were found. The Km value, which reflects the 
enzymatic affinities, was determined (Figs. 1 & 2). 
This Km value found was promising and was in the 
defined range
18,19
, showing the functional activity of 
the optimized AChE and BuChE. Galantamine was 
selected as test AChE and BuChE inhibitor for 
assessing the performance of the Huperzine-A for 
AChE and BuChE for determination of ligand affinity. 
Inhibition of enzymatic activity by galantamine was 
measured in the concentration range 0.2-500 M. As 
shown in the resulting dose-response curve (Fig. 1 ), 
the enzymatic activity decreased with increasing 
concentrations of the inhibitor galantamine, 
demonstrating that AChE and BuChE activity was 
indeed efficiently inhibited by Huperzine-A when 
compared to galantamine. The IC50 value was 
determined were found to be in relevance with reported 
data
20
, indicating that Huperzine-A has similar 
correlated enzymatic properties for inhibition of AChE 
and BuChE in comparison to Galantamine.  
Enzyme kinetics is the systematic study of 
chemical processes which are catalyzed by enzymes 
in or out the biological system. The rate of reaction is 
determined and the effect of concentration on enzyme 
kinetics is measured. Lineweaver-Burk plot is a 
graphical representation of enzyme kinetics. This 
method helps to reveal the competitive or non 
competitive inhibition of enzymes by the inhibitors. 
The Lineweaver-Burk plot obtained for kinetic studies 
showed that Huperzine-A is a competitive inhibitor of 
both the enzymes i.e. ACHE and BUCHE on the 
comparative study with Galantamine, an established 
inhibitor of AChE and not BuChE
21
. The exact 
mechanism of the inhibition and the detailed 
comparison of AChE and BuChE, however, were not 
done. Though inhibition of BuChE can be found but 
the inhibition constant is too high to be reached in the 
body when compared to Galantamine. AChE activity 
can be affected more easily. It is noteworthy that 
Huperzine-A is not a potent inhibitor of AChE. 
Huperzine-A, however, a reversible inhibitor of 
AChE which shows binding with aromatic residues  
in the active site of AChE. The formation of the 
AChE–Huperzine-A complex is rapid while the 
dissociation is slow. The (Figs. 1 & 2) obtained showed 
that ACHE showed lesser inhibition as compared to 
BUCHE both in comparison to Galantamine. Initially 
the enzyme kinetic showed the slow enzyme and 
 
 
Fig. 1 — (A) Inhibitory activity of Galantamine and Huperzine-A 
against Ache; (B) Inhibitory activity of Galantamine  
and Huperzine-A against BuChE. The results are expressed as 
mean ± standard error of the mean. Statistical comparison was 
performed using analysis of variance (ANOVA) followed by 
Bonferroni's test (*P< 0.001) 
 
 
Fig. 2 — Lineweaver-Burk reciprocal plot for Acetylcholinesterase 
and Butyrylcholinesterase inhibition of (A) Galantamine;  
(B) Huperzine-A 
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substrate reaction and dissociation in ACHE while 
rapid enzyme and substrate reaction while the slow rate 
of dissociation. The results obtained in enzymatic 
studies showed that there is a higher perspective for in 
vivo studies and positive result. The rate of enzyme 
kinetics gave a concrete base for further studies which 
needs to be explored further. The enzymatic study of 
Huperzine-A over these enzymes established one fact 
that Huperzine-A is a competitive inhibitor of both 
ACHE as well as BUCHE in comparison to 
Galantamine although some differences in the enzyme-
substrate reaction and dissociation. 
Automated docking technique was utilized to 
determine the ‘orientation’ of Huperzine-A with 
Acetylcholinesterase and Butyrylcholinesterase. (Fig. 2) 
indicate the interaction of Huperzine-A with the 
active pocket of enzymes. Huperzine-A demonstrated 
minimum binding energy with enzyme via  
non-covalent interaction (Table 1). These in silico 
observation corroborate the in vitro non competitive 
and competitive enzyme inhibitory activity of 
Huperzine-A. The binding of Huperzine-A (Fig. 3) 
involves direct hydrogen bonds between OH and N2 
of the ligand with 1ITB and 4EY7 respectively,  
 
 
Fig. 3 — Molecular docking studies of Huperzine-A against (A) Acetylcholinesterase; (B) Butyrylcholinesterase [(A) 2D-interactions & 
(B) 3D-interactions] 
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(Fig. 2). The interaction with 1ITB (Fig. 3) is critical 
for the inhibition of the human enzyme. The crystal 
structure of the complex of AChE and BUCHE with 
optically pure Huperzine-A at 2.35 Å and 2.50 Å 
resolutions respectively, shows an unexpected 
orientation for the inhibitor with surprisingly few 
strong direct interactions with protein residues to 
explain its high affinity. This structure is compared to 
the native structure of AChE devoid of any inhibitor 
as determined to the same resolution. An analysis of 
the affinities of structural analogues of Huperzine-A, 
correlated with their interactions with the protein, 
shows the importance of individual hydrophobic 
interactions between Huperzine-A and aromatic 
residues in the active-site of AChE and BUCHE. The 
structural analysis revealed that Huperzine-A bears no 
resemblance to ACHE & BUCHE and that the  
Huperzine-A–AChE complex and Huperzine-A–
BuChE complex binds to the active-site gorge of 
AChE with few direct contacts with the protein.  
Only one strong hydrogen bond is seen, as well  
as some hydrophobic interactions within the 
crystalline complex
21
. The 3D computer image of 
AChE–Huperzine-A, Huperzine-A–BuChE binding 
generated in the Raves study revealed how the 
Huperzine-A blocks the enzyme by sliding smoothly 
into the active site of AChE and BuChE where 
acetylcholine (ACh) is broken down, and latches onto 
this site via a large number of subtle chemical links. 
Further, this complex has been studied utilizing 
kinetic studies which revealed its competitive 
enzymatic inhibitory effect. The result obtained in 
kinetic studies via Ellman methods were very 
promising. It can be concluded that Huperzine-A 
shows competitive inhibition over both enzymes. The 
enzymatic study performed needs to be further 
explored with more parameters. 
 
Discussion 
With due course of increasing and developing drugs 
in brain cholinergic system and cognition impairment, 
cholinesterase inhibitor drugs have followed the 
finding that cholinergic pathways in the cerebral 
cortex and basal forebrain are played important role in 
cognitive deficit
22
. Further alteration in the cholinergic 
system may contribute to the enhancement of brain 
activity
23
. Galantamine tends to be established 
nootropic agent which is given in many cerebral 
related disorders like Alzheimer's disease, Parkinson’s 
etc. Drugs with single target functional components of 
cognition and memory always have limited success
24
. 
However, recent results for multifunctional drugs in 
treating neurodegenerative disorders have been 
encouraging and might provide greater symptomatic 
efficacy than a strategy of administering multiple 
single drugs with potentially different degrees of 
bioavailability, pharmacokinetics and metabolism
25,26
. 
Huperzine-A is isolated from a Chinese herb, which 
has neuroprotective effects that go beyond the 
inhibition of AChE and BUCHE. Here, we have 
outlined the in silico and in vitro study of Huperzine-
A, and demonstrated that it can target several 
molecular sites. The multiple effects of Huperzine-A 
on various sites of ACHE and BUCHE might 
stimulate endogenous protective processes or promote 
repair of damaged structures. Because most 
neurodegenerative diseases are characterized by 
progressive neuronal loss associated with the 
development of symptoms, the neuroprotective effects 
of Huperzine-A might benefit conditions such as 
Parkinson’s disease, amyotrophic lateral sclerosis or 
Huntington’s disease, by slowing down the 
neurodegenerative processes. In the in silico studies, it 
was apparent that Huperzine-A–AChE complex and 
Huperzine-A–BuChE complex impressively binds to 
the active-site showing possible structural alteration. 
The results obtained in docking studies showed that 
Huperzine-A could be non-competitive and 
competitive enzyme inhibitor which confirms the 
effect reported for the other biological molecules in 
numerous studies
27-31
. Owing to the results docking 
the enzyme inhibitory activity was further validated by  
in vitro studies. The inhibition of enzymes further 
validated the result. The Lineweaver-Burk plot showed 
that Huperzine-A is a competitive inhibitor of ACHE and 
BUCHE as compared to Galantamine though there were 
some differences seen in the enzyme-substrate reaction 
and dissociation. This study concluded that the structural 
affinity of huperzine makes it competitive inhibitor of 
ACHE and BUCHE. However, further clinical study is 
needed before we can make this conclusion. 
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